After AI Accelerates Target Discovery—How Custom Synthesis Fills the Compound Gap for Target Validation
I. AI Drug Discovery Enters Clinical Era—Target Identification Outpaces Compound Availability
July 2026 marks a milestone for AI-powered drug discovery. Insilico Medicine announced the initiation of a Phase III clinical trial for Rentosertib (ISM001-055), an oral small-molecule TNIK inhibitor for idiopathic pulmonary fibrosis—the first candidate drug whose both target and molecular structure were discovered and designed by AI to reach Phase III. The Phase III study is a randomized, double-blind, placebo-controlled trial enrolling 320 IPF patients across 47 centers in China. In the Phase IIa GENESIS-IPF study, the 60 mg once-daily arm showed a mean FVC improvement of 98.4 mL at 12 weeks, compared with a decline of 20.3 mL in the placebo group.
In the same month, Anthropic launched Claude Science for life sciences research, integrating over 60 scientific databases and announcing its own drug discovery programs for neglected diseases. Over 170 AI-discovered or AI-optimized drug candidates are now in clinical trials, making 2026 the most data-dense year for AI pharma.
AI is identifying new targets and designing novel molecules at unprecedented speed. But a structural bottleneck is emerging: AI-discovered targets require real compounds for validation—and these compounds are often unavailable from commercial catalogs, requiring custom synthesis.
II. Target Validation Demands High-Purity, Custom-Synthesized Tool Compounds
From computational prediction to bench validation—this is one of the most underestimated bottlenecks in drug discovery. AI can generate 100 new targets in a week, but each target's functional validation, pathway dissection, and phenotypic confirmation require high-quality tool compounds. Without reliable inhibitors or activators, AI-predicted targets remain lines of code.
Cdc42—From Basic Research to Clinical Translation
Cdc42 is a core member of the Rho family of small GTPases, regulating cytoskeletal reorganization, cell migration, polarity, and division. Aberrant Cdc42 activation has been implicated in cancer, neurological disorders, ophthalmological diseases, skin diseases, and vascular conditions.
MBQ-167, the first-in-class dual Rac/Cdc42 inhibitor, is currently in Phase I (NCT06075810) for advanced breast cancer. Preclinical data at AACR 2026 demonstrated that Rac/Cdc42 inhibitors simultaneously target both cancer cells and macrophage-like cells in the tumor microenvironment. The first clinical trial targeting CDC42 mutations was initiated in March 2026 for monogenic IL-18-driven autoinflammatory diseases.
As Cdc42-targeted therapies advance toward clinical translation, the demand for high-purity, selective Cdc42 inhibitor tool compounds is growing rapidly. However, the synthesis of such compounds involves complex chiral center construction and heterocyclic scaffold assembly—requiring robust custom synthesis capabilities.
Glutaminase—A Key Target in Tumor Metabolic Reprogramming
Glutamine is the second most avidly consumed molecule by cancer cells. Glutaminase catalyzes the first and rate-limiting step of glutamine metabolism.
A comprehensive review published in Pharmaceutics (July 2026) systematically examined 70 years of glutamine-targeted therapies, identifying glutaminase as a core target in combination therapies for multiple tumor types. Tumors with co-occurring KRAS and KEAP1 mutations exhibit survival dependency on glutaminase-mediated glutaminolysis. The novel boron-based glutamine analog ABBA has been shown to covalently inhibit kidney-type glutaminase and suppress triple-negative breast cancer cell proliferation.
The structural modification of glutamine analogs—from DON to ABBA to various prodrug derivatives—epitomizes the need for custom synthesis. Researchers require not just a single standard compound, but a series of structural analogs for SAR studies and selectivity optimization. This is precisely where custom synthesis services deliver value.
DRP1—A Core Target in Mitochondrial Dynamics
DRP1 is a key GTPase regulating mitochondrial fission. DRP1-mediated excessive fission has been linked to liver fibrosis, diabetic retinopathy, cancer drug resistance, and cardiovascular disease.
A study in Free Radical Biology and Medicine (March 2026) demonstrated that the DRP1 inhibitor Mdivi-1 restored mitochondrial homeostasis and significantly alleviated CCl₄-induced liver fibrosis in vivo. Research published in June 2026 revealed that DRP1-mediated mitochondrial fission is the dominant mechanism driving acquired sorafenib resistance in liver cancer cells (HR = 3.899, 95% CI: 1.167–13.022, p = 0.027). A July 2026 study further showed that Mdivi-1 alleviates high glucose-induced excessive mitochondrial fission, protecting against diabetic retinopathy.
The chemical space of DRP1 inhibitors remains largely underexplored. Currently available tool compounds are limited in structural diversity, and most are early-stage hits with significant room for PK and selectivity optimization—posing ongoing demands for custom synthesis and molecular design.
III. The Core Bottleneck in Target Validation: Compound Availability
These three target areas point to a common challenge: AI and frontier biology are rapidly identifying new targets, but the tool compounds required for validation are often unavailable in any commercial compound library.
Even established benchmark compounds (such as ML141, DON, and Mdivi-1) face persistent challenges:
●Inconsistent purity—affecting experimental reproducibility
●Supply instability—common tool compounds frequently out of stock
●Lack of structural analogs—single compounds cannot meet SAR study needs
●Scale-up bottlenecks—consistency across different batch sizes is difficult to maintain
These problems cannot be solved by "buying off-the-shelf"—they require custom synthesis.
IV. Beixinke Chem—Custom Synthesis Solutions for Target Validation
Beixinke Chem is a custom synthesis service provider specializing in inhibitor small molecules, heterocyclic intermediates, and chiral building blocks, serving pharmaceutical R&D labs worldwide.
Our core capabilities cover the complete chain from target validation tool compounds to drug candidate synthesis:
Beixinke Chem is a custom synthesis service provider specializing in inhibitor small molecules, heterocyclic intermediates, and chiral building blocks, serving pharmaceutical R&D labs worldwide.
Our core capabilities cover the complete chain from target validation tool compounds to drug candidate synthesis:
[Retrosynthetic analysis] Design accessible, cost-effective, and efficient synthetic routes
[Chiral construction] Chiral resolution, chiral catalysis, asymmetric synthesis for stereochemical requirements
[Heterocyclic assembly] Construction of complex heterocyclic scaffolds including piperidines, pyrrolidines, azetidines
[Process scale-up] From milligrams to kilograms, maintaining purity and reproducibility
[Analytical support] Full HPLC, LC-MS, NMR data for structural confirmation and purity verification
For the three target areas discussed above, we offer the following custom synthesis support:
[Cdc42 inhibitors] Stereoselective construction of chiral piperidine/pyrrolidine scaffolds; introduction of fluorinated aromatic building blocks
[Glutamine analogs] Safe scale-up of α-diazo carbonyl compounds; synthesis of non-natural amino acid derivatives
[DRP1 inhibitors] Scaffold diversification of quinazolinone core; design and synthesis of cell-permeability-optimized analogs
We provide not just standard compounds, but also a series of structural analogs around your target of interest to support your SAR studies and target validation efforts.
Why Beixinke Chem?
R&D flexibility: 50mg–500g, covering everything from screening to in vivo studies
Purity and data transparency: Every batch comes with HPLC, LC-MS, and NMR full spectra
Rapid response: Typically deliver feasibility assessments and quotations within 24 hours
IP protection: Strict confidentiality agreements to ensure research security
Contact us with your target molecule or target-of-interest requirements—we will provide a custom synthesis feasibility assessment within 24 hours.